首页> 外文期刊>Nature medicine >Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
【24h】

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

机译:HLA-Ig包被的人工抗原呈递细胞对抗原特异性细胞毒性T细胞的离体诱导和扩增。

获取原文
获取原文并翻译 | 示例
           

摘要

Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T lymphocytes (CTLs). As a result, there are only limited reports of expansion of antigen-specific CTLs to the levels required for clinical therapy. To address this issue, artificial antigen-presenting cells (aAPCs) were made by coupling a soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) and CD28-specific antibody to beads. HLA-Ig-based aAPCs were used to induce and expand CTLs specific for cytomegalovirus (CMV) or melanoma. aAPC-induced cultures showed robust antigen-specific CTL expansion over successive rounds of stimulation, resulting in the generation of clinically relevant antigen-specific CTLs that recognized endogenous antigen-major histocompatibility complex complexes presented on melanoma cells. These studies show the value of HLA-Ig-based aAPCs for reproducible expansion of disease-specific CTLs for clinical approaches to adoptive immunotherapy.
机译:过继免疫疗法有望作为一种治疗癌症和传染病的方法,但是由于缺乏可再生的方法来产生治疗数量的抗原特异性CD8(+)细胞毒性T淋巴细胞(CTL)而受到阻碍。结果,仅有有限的报道将抗原特异性CTL扩增至临床治疗所需的水平。为了解决这个问题,通过将可溶性人白细胞抗原-免疫球蛋白融合蛋白(HLA-Ig)和CD28特异性抗体偶联到珠子上来制造人工抗原呈递细胞(aAPC)。基于HLA-Ig的aAPC用于诱导和扩增对巨细胞病毒(CMV)或黑色素瘤具有特异性的CTL。在连续几轮刺激中,aAPC诱导的培养物显示出强大的抗原特异性CTL扩增,导致产生了临床相关的抗原特异性CTL,这些CTL识别了黑色素瘤细胞上呈现的内源性抗原-主要组织相容性复合物。这些研究表明,基于HLA-Ig的aAPC对于疾病特异性CTL的可再现性扩展,可用于过继免疫疗法的临床方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号